Key result
Mitral valve replacement in severe pulmonary hypertension shows ~93% 2-year survival and functional improvements.
Why the study?
The study was conducted to assess the clinical, echocardiographic, and hemodynamic changes occurring in patients with severe pulmonary hypertension after mitral valve replacement in the early and mid-term period.
Does mitral valve replacement improve clinical, echocardiographic, and hemodynamic outcomes in patients with mitral valve disease and severe pulmonary hypertension?
Cohort (n=40)
No
Does mitral valve replacement improve clinical, echocardiographic, and hemodynamic outcomes in patients with mitral valve disease and severe pulmonary hypertension?
Mitral valve replacement is safe and effective in patients with severe pulmonary hypertension, yielding significant functional and hemodynamic improvements at 2 years.
Answers are grounded in this paper and cite their sources.
Supports mitral valve replacement in severe pulmonary hypertension; hypothesis-generating and requires randomized confirmation before practice change.
Background: Pulmonary hypertension (PH) occurs with an overall prevalence estimated at 15 per one million individuals. PH is only defined in the resting state and is present when the catheter derived mean pulmonary artery pressure (mPAP) exceeds 25 mmHg. Objective: To assess the clinical, echocardiographic, and hemodynamic changes occurring to patients with severe pulmonary hypertension after mitral valve replacement in early and mid-term period. Patients and methods: This study included 40 patients, who underwent mitral valve replacement for mitral valve disease with severe PH > 50 mmHg) were studied prospectively for immediate and midterm (after 2 years) postoperative hemodynamics and outcomes. This study was conducted in Shebeen El-Koom Teaching Hospital during the period August 2016 to December 2019. Results: The early and mid-term results of mitral valve replacement in patients with pulmonary hypertension were good with functional improvement and reduction of pulmonary hypertension. By the end of the study, some complications, which were successfully managed, were reported and survival at two years was 92.5%. Conclusion: Mitral valve replacement (MVR) was safe and effective operation even in patients with severe pulmonary hypertension (PH) with acceptable operative mortality, and a significant improvement in echocardiographic parameters, pulmonary pressure, and NYHA classification.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2021) conducted a cohort in Mitral valve disease with severe pulmonary hypertension (n=40). Mitral valve replacement was evaluated on Survival at two years. Mitral valve replacement in patients with severe pulmonary hypertension was safe and effective, yielding a 2-year survival rate of 92.5% alongside significant functional improvements.
Synapse has enriched 10 related papers. Consider them for comparative context: